IMPROVED IMMUNODIAGNOSTIC ASSAYS USING REDUCING AGENTS

Abstract: The present invention relates to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent. The present invention also relates to a method for purifying a cysteine containing recombinantly expressed protein comprising at least 2, preferably 3 or 4 and even more preferably all of the following steps: (a) sulphonation of a lysate from recombinant host cells or lysis of recombinant host cells in the presence of guanidinium chloride followed by a subsequent sulphonation of the cell lysate, (b) treatment with a zwitterionic detergent, preferably after removal of the cell debris, (c) purification of the sulphonated version of the recombinant protein or purification of the sulphonated version of the recombinant protein with subsequent removal of the zwitterionic detergent, with said purification being preferably chromatography, more preferably a Ni-IMAC chromatography with said recombinant protein being a His-tagged recombinant protein, (d) desulphonation of the sulphonated version of the recombinant protein, preferably with a molar excess of DTT, (e) storage in the presence of a molar excess of DTT. The present invention also relates to novel HCV NS3 sequences as depicted in Figures 1-8.

Description: 1 IMPROVED IMMUNODIAGNOSTIC ASSAYS USING REDUCING AGENTS FIELD OF THE INVENTION The present invention relates to the field of diagnosis and treatment of HCV infection. More particularly, the present invention relates to HCV NS3 helicase and its uses. Also the present invention relates to improved immuno diagnostic assays. BACKGROUND OF THE INVENTION Hepatitis C Viruses (HCV) constitute a genus within the Flaviviridae, with closest homology to the hepatitis G and GB viruses, and Pestiviruses. The positive-stranded RNA genome encodes at least 9 proteins. Core, El, and E2 constitute the structural proteins. NS2, NS3, NS4A, NS4B, NS5A, and NS5B are non- structural (NS) proteins. HCV isolates display high levels of sequence heterogeneity allowing classification into at least 11 types and 90 subtypes (Maertens and Stuyver, 1997). HCV infection of the human liver is often clinically benign, with mild icterus in the acute phase. The disease may even go unnoticed in some cases of acute resolving hepatitis C. In the majority (>70%) of cases, however, HCV infection leads to chronic persistent or active infection, often with complications of liver cirrhosis and auto-immune disorders. Hepatocellular carcinoma may occur after about 20 to 35 years (Saito et al, 1990), sometimes even without the intermediate phase of cirrhosis. No prophylaxis is available today and treatment with interferon-alpha (IFN-α) only leads to long-term resolution in about 4 to 36% of treated cases, depending on the HCV genotype (Maertens and Stuyver, 1997). Since productive culture methods for HCV are currently not available, and since only minute amounts of HCV antigens circulate in the infected patient, direct detection of HCV particles cannot be performed routinely, and indirect diagnosis is only possible using cumbersome amplification techniques for HCV RNA detection. Unlike with many other viral infections, HCV particles generally persist in the blood, liver, and lymphocytes despite the presence of cellular and humoral immune response to most of the HCV proteins. HCV antibodies can be conveniently 2 detected by Elisa techniques which allow high throughput screening in blood banks and clinical laboratories. Supplementary antibody testing is required and is now mandatory in most countries. True HCV reactivity is thus discriminated from false reactivity, which may be caused by nonspecific binding of serum or plasma immunoglobulines or anti-idiotypic components to the coating or blocking reagents, or to contaminants present in HCV antigen preparations, or even to fusion parts or non-specific regions of the recombinant antigens themselves (McFarlane et al, 1990). HCV RNA detection by PCR or branched DNA (bDNA) techniques have recently been introduced to monitor chronic HCV disease, especially during therapy. Surprisingly, HCV RNA detection is sometimes employed to confirm HCV Ab screening tests, despite the fact that only -70-94% of repeatedly HCV Ab positive patient samples are positive by nested PCR (Marin et al., 1994). Of HCV Ab positive blood donors, who usually present with milder forms of the disease and low HCV RNA levels, confirmation by nested PCR is usually in the order of -40% (Waumans et al., 1993; Stuyver et al, 1996). Strip-based assays therefore provide the only reliable alternative for HCV Ab confirmation. Even in the case of an indeterminate result in the confirmatory assay, serological follow up of the patient rather than HCV RNA detection is advisable (Di Bisceglie et al, 1998). Since native HCV antigens are not available in sufficient quantities, such confirmatory assays incorporate synthetic peptides and/or recombinant fragments of HCV proteins. One of the most critical issues in the confirmation of antibodies constitutes the reactivity of the NS3 protein (Zaaijer et al., 1994). NS3 antibodies often appear first in seroconversion series and the reactivity of the NS3 protein seems to be different in the different commercial assays available today . Innogenetics introduced the concept of strip technology in which usually a combination of synthetic peptides and recombinant proteins are applied as discrete lines in an ordered and easily readable fashion. The LNNO-LIA HTV Ab tests have proven to be superior to routinely used western blots (Pollet et al., 1990). The Line Immuno Assay allows multiparameter testing and thus enables incorporation of cutoff and other rating systems, sample addition control, as well as testing for false reactivity to non-HCV proteins used as carrier or fusion partner required for some antigens in the Elisa test. In principle, the test format allows to combine antigens of different aetiological agents or phenotypically linked conditions into a single test. The ΓNNO-LIA HCV Ab III is a 3rd generation Line Immuno Assay which incorporates HCV antigens derived from the Core region, the E2 hypervariable region (HVR), the NS3 3 helicase region, and the NS4A, NS4B, and NS5A regions. In theihird generation assay, highly purified recombinant subtype lb NS3 protein and E2 peptides enabled superior sensitivity while safeguarding the reliable specificity which is characteristic of peptide-based tests (Peeters et al., 1993). Perhaps one of the most important features of this assay is its unprecedented correlation with HCV RNA positivity (Claeys et al, 1992; De Beenhouwer et al., 1992). The antigens are coated as 6 discrete lines on a nylon strip with plastic backing. In addition, four control lines are coated on each strip: anti-streptavidin, 3+ positive control (anti- human Ig), 1+ positive control (human IgG), and the ± cutoff line (human IgG). A diluted test sample is incubated in a trough together with the LI A III strip. If present in the sample, HCV antibodies will bind to the HCV antigen lines on the strip. Subsequently, an affinity-purified alkaline phosphatase labelled goat anti-human IgG (H+L) conjugate is added and reacts with specific HCV antigen/antibody complexes if previously formed. Incubation with enzyme substrate produces a chestnut-like color, the intensity of which is proportionate to the amount of HCV- specific antibody captured from the sample on any given line. Color development is stopped with sulphuric acid. If no HCV-specific antibodies are present, the conjugate only binds to the ±, 1+, and 3+ control lines. If the addition of sample is omitted, only the ± and 1+ control lines will be stained. DEFINITIONS The following definitions serve to illustrate the different terms and expressions used in the present invention. The term 'HCV NS3' protein' refers to a polypeptide or an analogue thereof (e.g. mimotopes) comprising an amino acid sequence (and/or amino acid analogues) defining at least one HCV epitope of either HCV NS3 protease or helicase. The term 'hepatitis C virus envelope protein' refers to a polypeptide or an analogue thereof (e.g. mimotopes) comprising an amino acid sequence (and/or amino acid analogues) defining at least one HCV epitope of either the El or the E2 region (see WO 96/04385 of which the contents are hereby incorporated by reference) . It should also be understood that the isolates (biological samples) used in the examples 4 section of the present invention were not intended to limit the scope of the invention and that any HCV isolate belonging to type 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or any other new genotype of HCV is a suitable source of HCV sequence for the practice of the present invention. The HCV antigens used in the present invention may be full-length viral proteins, substantially full-length versions thereof, or functional fragments thereof (e.g. fragments which are not missing sequence essential to the formation or retention of an epitope). Furthermore, the HCV antigens of the present invention can also include other sequences that do not block or prevent the formation of any conformational epitope of interest. The presence or absence of a conformational epitope can be readily determined though screening the antigen of interest with an antibody (polyclonal serum or monoclonal antibody) and comparing its reactivity to that of a denatured version of the antigen which retains only linear epitopes (if any). When in such screening polyclonal antibodies are used, it may be advantageous to adsorb the polyclonal serum first with the denatured antigen and see if it retains antibodies to the antigen of interest. The term 'fusion polypeptide' intends a polypeptide in which the antigen(s), in particularly HCV antigen(s), are part of a single continuous chain of amino acids, which chain does not occur in nature. The HCV antigens may be connected directly to each other by peptide bonds or be separated by spacer amino acid sequences. The fusion polypeptides may also contain amino acid sequences exogenous to HCV. The term 'solid phase' or 'solid support' means a solid body to which the individual HCV antigens or the fusion polypeptide comprised of HCV antigens are bound covalently or by noncovalent means such as by hydrophobic adsorption. Examples of solid phases are microtiter plates, membrane strips such as nylon or nitrocellulose strips, and silicon chips. The term 'biological sample' intends a fluid or tissue of a mammalian individual (e.g. an anthropoid, a human) that commonly contains antibodies produced by the individual, more particularly antibodies against HCV. The fluid or tissue may also contain HCV antigen. Such components are known in the art and include, without limitation, blood, plasma, serum, urine, spinal fluid, lymph fluid, secretions of the respiratory, intestinal or genitourinary tracts, tears, saliva, milk, white blood cells and myelomas. Body components include biological liquids. The term 'biological liquid' refers to a fluid obtained from an organism. Some biological fluids are used as a source of other products, such as clotting factors (e.g. Factor VIII), serum 5 albumin, growth hormone and the like. In such cases, it is important that the source of biological fluid be free of contamination by virus such as HCV. ■ The term ' immunologically reactive' means that the antigen in question will react specifically with anti-HCV antibodies present in a body component from an HCV infected individual or an immunized individual. The term 'immune complex' intends the combination formed when an antibody binds to an epitope on an antigen. The terms El and E2 as used herein are fully described in WO 96/04385 of which the content is incorporated by reference in the present description. The term 'purified' as applied to proteins herein refers to a composition wherein the desired protein comprises at least 35% of the total protein component in the composition. The desired protein preferably comprises at least 40% , more preferably at least about 50%, more preferably at least about 60% , still more preferably at least about 70%, even more preferably at least about 80%, even more preferably at least about 85%, even more preferably at least about 90%, and most preferably at least about 95% of the total protein component. The composition may contain other compounds such as carbohydrates, salts, lip ids, solvents, and the like, without affecting the determination of the percentage purity as used herein. An 'isolated' HCV protein intends an HCV protein composition that is at least 35 % pure. The term 'essentially purified proteins' refers to proteins purified such that they can be used for in vitro diagnostic methods and as a therapeutic compound. These proteins are substantially free from cellular proteins or DNA, vector-derived proteins or DNA, or other HCV viral components. Usually these proteins are purified to homogeneity (at least 80% pure, preferably, 85 %, more preferably, 90%, more preferably 95 % , more preferably 97%, more preferably 98%, more preferably 99%, even more preferably 99.5%, and most preferably the contaminating proteins should be undetectable by conventional methods like SDS-PAGE and silver staining. The term 'recombinantly expressed' used within the context of the present invention refers to the fact that the proteins of the present invention are produced by recombinant expression methods be it in prokaryotes, or lower or higher eukaryotes as discussed in detail below. The term 'lower eukaryote' refers to host cells such as yeast, fungi and the like. Lower 6 eukaryotes are generally (but not necessarily) unicellular. Preferred lower eukaryotes are yeasts, particularly species within Saccharomyces, Schizosaccharomyces, Klyveromyces, Pichia (e.g. Pichia pastoris) , Hansenula (e.g. Hansenula polymorpha) , Yarowia, Schwanniomyces , Zygosaccharomyces and the like. Saccharomyces cerevisiae, S. carlsbergensis and K. lactis are the most commonly used yeast hosts. The term 'prokaryotes' refers to hosts such as E. coli, Lactobacillus, Lactococcus, Salmonella, Streptococcus, Bacillus subtilis or Streptomyces. Also these hosts are contemplated within the present invention. The term 'higher eukaryote' refers to host cells derived from higher animals, such as mammals, reptiles, insects, and the like. Presently preferred higher eukaryote host cells are derived from Chinese hamster (e.g. CHO), monkey (e.g. COS and Vero cells), baby hamster kidney (BHK), pig kidney (PK15), rabbit kidney 13 cells (RK13), the human osteosarcoma cell line 143 B, the human cell line HeLa and human hepatoma cell lines like Hep G2, and insect cell lines (e.g. Spodoptera frugiperda) . The host cells may be provided in suspension or flask cultures, tissue cultures, organ cultures and the like. Alternatively the host cells may also be transgenic animals. The term 'polypeptide' refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogues of an amino acid (including, for example, unnatural amino acids, PNA, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring. The term 'recombinant polynucleotide or nucleic acid' intends a polynucleotide or nucleic acid of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature. The term 'recombinant host cells' , 'host cells' , 'cells' , 'cell lines' , 'cell cultures' , and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as 7 unicellular entities refer to cells which can be or have been, used as recipients for a recombinant vector or other transfer polynucleotide, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation. The term 'replicon' is any genetic element, e.g. , a plasmid, a chromosome, a virus, a cosmid, etc., that behaves as an autonomous unit of polynucleotide replication within a cell; i.e. , capable of replication under its own control. The term 'vector' is a replicon further comprising sequences providing replication and/or expression of a desired open reading frame. The term 'control sequence' refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and terminators; in eukaryotes, generally, such control sequences include promoters, and may include enhancers. The term 'control sequences' is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences which govern secretion. The term 'promoter' is a nucleotide sequence which is comprised of consensus sequences which allow the binding of RNA polymerase to the DNA template in a manner such that mRNA production initiates at the normal transcription initiation site for the adjacent structural gene. The expression 'operably linked' refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence Operably linked' to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. An 'open reading frame' (ORF) is a region of a polynucleotide sequence which encodes a polypeptide and does not contain stop codons in the reading frame selected; this region may represent a portion of a coding sequence or a total coding sequence. A 'coding sequence' is a polynucleotide sequence which is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory 8 sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5 '-terminus and a translation stop codon at the 3 '-terminus. A coding sequence can include but is not limited to mRNA, viral RNA, DNA (including cDNA), and recombinant polynucleotide sequences. As used herein, 'epitope' or 'antigenic determinant' means an amino acid sequence that is immunoreactive. Generally an epitope consists of at least 3 to 4 amino acids, and more usually, consists of at least 5 or 6 amino acids, sometimes the epitope consists of about 7 to 8, or even about 10 amino acids. As used herein, an epitope of a designated polypeptide denotes epitopes with the same amino acid sequence as the epitope in the designated polypeptide, and immunologic equivalents thereof. Such equivalents also include strain, subtype (= genotype), or type(group)-specific variants, e.g. of the currently known sequences or strains belonging to genotypes la, lb, lc, Id, le, If, 2a, 2b, 2c, 2d, 2e, 2f, 2g, 2h, 2i, 3a, 3b, 3c, 3d, 3e, 3f, 3g, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 4k, 41, 5a, 5b, 6a, 6b, 6c, 7a, 7b, 7c, 8a, 8b, 9a, 9b, 10a, 11a, 12a or any other newly defined HCV (sub)type. It is to be understood that the amino acids constituting the epitope need not be part of a linear sequence, but may be interspersed by one or more series of any number of amino acids, thus forming a conformational epitope. The term 'immunogenic' refers to the ability of a substance to cause a humoral and/ or cellular response, whether alone or when linked to a carrier, in the presence or absence of an adjuvant. 'Neutralization' refers to an immune response that blocks the infectivity, either partially or fully, of an infectious agent. A 'vaccine' is an immunogenic composition capable of eliciting protection against HCV, whether partial or complete. A vaccine may also be useful for treatment of an individual, in which case it is called a therapeutic vaccine. The term 'therapeutic' refers to a composition capable of treating HCV infection. The term 'effective amount' refers to an amount of epitope-bearing polypeptide sufficient to induce an immunogenic response in the individual to which it is administered, or to otherwise detectably immunoreact in its intended system (e.g., immunoassay). Preferably, the effective amount is sufficient to effect treatment, as defined above. The exact amount necessary will vary according to the application. The term 'antibody' refers to polyclonal or monoclonal antibodies. The term 'monoclonal antibody' refers to an antibody composition having a homogeneous antibody population. The term 9 is not limited regarding the species or source of the antibody, nor is it intended to be limited by the manner in which it is made. It should be noted that also humanized antibodies, single chain antibody or any other fragment thereof which has largely retained the specificity of said antibody are covered by the present invention. As used herein, the term 'humanized antibody' means that at least a portion of the framework regions of an immunoglobulin are derived from human immunoglobulin sequences. As used herein, the term 'single chain antibody 1 refers to antibodies prepared by determining the binding domains (both heavy and light chains) of a binding antibody, and supplying a linking moiety which permits preservation of the binding function. As used herein, the term 'fragments (of antibodies)' refers to F ab , F (ab)2 , F v , and other fragments which retain the antigen binding function and specificity of the parent antibody. AIMS OF THE INVENTION It is an aim of the present invention to provide improved HCV diagnostic assay components and therapeutic proteins. More particularly it is an aim of the present invention to provide improved HCV NS3 protein preparations for use in HCV antibody diagnosis and/or HCV treatment. It is further an aim of the present invention to provide a method for increasing the reactivity of HCV antibodies with recombinant or synthetic NS3 helicase protein or part thereof present on a solid phase. It is also an aim of the present invention to provide a novel method for purifying cysteine containing recombinant proteins, more particularly recombinant HCV proteins. It is also an aim of the present invention to provide new HCV NS3 protein encoding sequences. It is also an aim of the present invention to provide new HCV NS3 protein encoding sequences of which the product does not react with falsly positive HCV samples. It is also an aim of the present invention to provide a method for detecting the nucleic acids of the invention. It is also an aim of the present invention to provide probes and primers for the detection 10 of the nucleic acids of the invention. It is also an aim of the present invention to provide a diagnositic kit for the detection of the nucleic acids of the invention. It is another aim of the present invention to provide new HCV NS3 polypeptides. It is another aim of the present invention to provide new HCV NS3 polypeptides which do not react with falsly positive HCV samples. It is another aim of the present invention to provide a pharmaceutical composition to prevent or treat HCV infection. It is another aim of the present invention to provide a method for the detection of the polypeptides of the invention. It is another aim of the present invention to provide antibodies to the polypeptides of the present invention for use in passive immunization and/or therapy. It is another aim of the present invention to provide a method for the production of the polypeptides of the invention. All the aims of the present invention are considered to have been met by the embodiments as set out below. DETAILED DESCRIPTION OF THE INVENTION The present invention relates more particularly to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent. As is demonstrated in the Examples section the present inventors have found that the presence of a reducing agent such as DTT, besides an antigen coated to a solid phase, renders a solid phase immunassay coupled antigen much more reactive with antibodies directed to said antigen. Also in solution, the antigen is rendered more reactive by reduction. A reducing agent according to the present invention is any agent which achieves reduction of S-S disulfide bridges. Reduction of the 'S-S' disulfide bridges is a chemical reaction whereby the disulfides are reduced to thiol (-SH). The disulfide bridge breaking agents and methods disclosed in WO 96/04385 are hereby incorporated by reference in the present description. 'S-S' Reduction can be obtained by (1) enzymatic cascade pathways or by 11 (2) reducing compounds. Enzymes like thioredoxin, glutaredoxin are known to be involved in the in vivo reduction of disulfides and have also been shown to be effective in reducing 'S- S' bridges in vitro. Disulfide bonds are rapidly cleaved by reduced thioredoxin at pH 7.0, with an apparent second order rate that is around 10 4 times larger than the corresponding rate constant for the reaction with DTT. The reduction kinetic can be dramatically increased by preincubation the protein solution with 1 mM DTT or dihydrolipoamide (Holmgren, 1979). Thiol compounds able to reduce protein disulfide bridges are for instance Dithiothreitol (DTT), Dithioerythritol (DTE), β-mercaptoethanol, thiocarbamates, bis(2-mercaptoethyl) sulfone and N,N'-bis(mercaptoacetyl)hydrazine, and sodium-dithionite. Reducing agents without thiol groups like ascorbate or stannous chloride (SnCl 2 ), which have been shown to be very useful in the reduction of disulfide bridges in monoclonal antibodies (Thakur et al., 1991), may also be used for the reduction of NS3. Sodium borohydride treatment has been shown to be effective for the reduction of disulfide bridges in peptides (Gailit, 1993). Tris (2-carboxyethyl)phosphine (TCEP) is able to reduce disulfides at low pH (Burns et al. , 1991). Selenol catalyses the reduction of disulfide to thiols when DTT or sodium borohydride is used as reductant. Selenocysteamine, a commercially available diselenide, was used as precursor of the catalyst (Singh and Kats, 1995). The present invention relates more particularly to a method for producing an immunoassay as defined above wherein said reducing agent is added to said solid phase during the steps of coating, blocking and/or fixation of said antigen to said solid phase. The present invention also relates to a method for carrying out an immunoassay as defined above wherein said reducing agent is added during the step of pretreatment of the solid phase. Coating conditions can vary widely as known by the skilled person and involves applying to a solid phase the protein and allowing a reaction to occur resulting in the binding of the protein to the solid phase. Binding can be, but is not restricted to, covalently hydrophobic or ionic bonds, Van Der Waels forces or hydrogen bridges. Different buffers known by the skilled man may be used for this step, including but not limited to carbamate and phosphate buffers. Blocking can occur via any method known in the art and can for instance also be performed using albumin, serum proteins, polyvinylpyrolidone (PVP), detergents, gelatines, 12 polyvinylalcohol (PVA) or caseϊne. Fixation can occur according to any method known in the art. Further examples of blocking, fixation and coating conditions are given in the Examples section. The present invention relates even more particularly to a method as defined above wherein said reducing agent is added to said solid phase during the step of coating of the antigen to the solid phase. Examples of coating buffers are given in the Examples section. All other known coating buffers known in the art also form part of the present disclosure. The present invention relates also to a method as defined above, wherein said reducing agent is added to said solid phase during the step of blocking said solid phase, comprising the antigen which had been applied thereto in the presence or absence of a reducing agent. Examples of blocking buffers are given in the Examples section. All other known blocking buffers known in the art also form part of the present disclosure. The present invention relates also to a method as defined above, wherein said reducing agent is added to said solid phase during the step of fixation of the coated antigen to said solid phase comprising the antigen which had been applied thereto in the presence or absence of a reducing agent. The fixation step may also have been preceded by a blocking step in the presence or absence of a reducing agent. Examples of fixation buffers are given in the Examples section. All other known fixation buffers known in the art also form part of the present disclosure. The present invention also relates to a method for carrying out an immunoassay as defined above wherein said reducing agent is added during the step of pretreatment of the solid phase before addition of the sample. Pretreatment of the plates can be done with plates that have been treated with a reducing agent in the coating, blocking and/or fixation step or with plates that have not been previously treated with a reducing agent. Finally, the reducing agent may also be added during any further steps carried out in enzyme immunoassays, as part of the present invention, possibly after application of a reducing agent in one or more of the above 4 steps of coating, blocking, fixation and/or pretreatment. Such further steps include but are not limited to incubation the antibodies, detecting bound antibodies and color development. The present invention relates preferably to a method as defined above wherein said 13 reducing agent is DTT, DTE or TCEP. The present invention relates also to a method as defined above wherein said reducing agent is used in a concentration range of 0.1 mM to 1 M, more particularly from 0.5 mM to 500 mM, even more particularly from 1 mM to 250 mM, most partcularly from 1 to 50 mM. Some applications may require ranges from 0.5 to 50 mM, 1 to 30 mM, 2 to 20 mM, 5 to 15 mM, or about 10 mM reducing agent. Other applications require DTT concentrations of 50- 500 mM, 100-300 mM or 200 mM. DTT is particularly preferred as a reducing agent. The present invention also relates to a method as defined above wherein said antigen is an HCV NS3 protein. More particularly an HCV NS3 helicase. Also preferred is an HCV envelope protein such as El and/or E2 protein. Also any other protein known in the art may react better with antibodies against said protein when the protein is added to the solid phase in the presence of DTT, or treated with DTT thereafter. The present invention also relates to a method as described above wherein said solid phase immunoassay comprises a combination of antigens of different aetiological agents or phenotypically linked conditions. The present invention also relates to a solid phase immunoassay produced by a method as defined above. More particularly, a kit containing at least a solid phase such as a microtiteφlate, a membrane strip or silicon chip which contains an antigen in the presence of a reducing agent. More particularly, the present invention relates to an ELISA produced by a method as defined above. In a preferred embodiment, the present invention relates to an ELISA produced by a method as defined above wherein said reducing agent is preferably added in the coating and/or fixation steps. In one preferred embodiment, the reducing agent can be applied in the coating step. In another preferred embodiment, the reducing agent can be applied in the fixation step. In a particularly preferred embodiment the reducing agent is added in both the coating and the fixation step. In another preferred embodiment, the present invention relates to an ELISA produced by a method as defined above wherein said reducing agent is added during pretreatment of the plates before addition of the sample. Pretreatment of the plates can be done with plates that have been treated with a reducing agent in the coating and/ or fixation step or with plates that 14 have not been previously treated with a reducing agent. ^The reducing agent may also be added during any further steps carried out in enzyme immunoassays. Such further steps include but are not limited to incubation the antibodies, detecting bound antibodies and color development. The present invention also relates to an Line Immunoassay (LIA) produced by a method as defined above. In a preferred embodiment, the present invention relates to a Line Immunoassay (LIA) produced by a method as defined above wherein said reducing agent is preferably added in the blocking step and/or washing step. The reducing agent may also be added during any further steps in producing or carrying out the enzyme immunoassays. Such further steps include but are not limited to fixation, pretreatment, incubation the antibodies, detecting bound antibodies and color development. The present invention also relates to a QUICK assay produced by a method as defined above. In a preferred embodiment, the present invention relates to a QUICK assay produced by a method as defined above wherein said reducing agent is preferably added during the coating of the antigen onto the strip. The QUICK assay is a lateral flow assay in which the antigens are coated onto the strips by spaying. In this assay, the reducing agent is preferably added to the spray solution. The reducing agent may also be added during any further steps in producint or carrying out the enzyme immunoassays. Such further steps include but are not limited to blocking, fixation, pretreatment, incubation the antibodies, detecting bound antibodies and color development. The present invention also relates to the use of an assay as defined above for in vitro diagnosis of antibodies raised against an antigen as defined above. The present invention also relates to an HCV NS3 protein treated by a method comprising the steps of sulphonation and subsequent desulphonation. Sulphonation and desulphonation is a reaction whereby -SO 3 groups are introduced or removed respectively from the protein. Sulphonation is defined as a process where thiolgroups (SH) on proteins (R) and disulphide bonds are converted to S-Sulphonates, according to the following reactions: RSH — > RS-SO 3 - (1) RS-SR + 2 -SO + H 2 O - > 2 RS-SO 3 + 2 OH " (2) 15 The products of the reactions are S-Sulphoproteins which are usually stable at neutral pH. Reaction (1) can be obtained by incubation the protein solution with tetrathionate at pH > 7 (Inglis and Liu, 1970). Reaction (2) proceeds to completion in the presence of copper ions (Cole, 1967). Chan (1968) has shown that treatment of protein with sodium sulfite and catalytic amounts of cysteine in the presence of oxygen gives sulpho-proteins. Desulfonation can be obtained (1) by an excess of competitive -SH (thiol) groups, (2) by reducing agents or (3) by incubation in non-neutral pH conditions. RS-SO 3 " + R'SH — > RSH + R'S-SO^ RS-SO 3 " + reducing agent — > RSH Competitive thiol groups may be obtained from low molecular weight compounds or from proteinacous -SH groups. Examples of mono- or dithiol containing compounds are: cysteine, cystean ine, reduced gluthation, N-acetyl cysteine, homocysteine, β-mercaptoethanol, thiocarbamates, bis(2-mercaptoethyl)sulphone (BMS) and N,N'-bis(mercaptoacetyl)hydrazine (BMH), 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB or Elman's reagent), Dithiotreitol (DTT) and Dithioerythrithiol (DTE) . The present invention further relates to an HCV NS3 protein as defined above which is additionally treated with a zwitterionic detergent. Empigen is known as betaine and is a particularly preferred example of a zwitterionic detergent. Other suitable detergents are known by the skilled man and are reviewed also in WO 96/04385. The present invention further relates to a method for purifying a cysteine containing, recombinantly expressed protein, comprising at least 2, preferably 3 or 4, and even more preferably, all of the following steps: (a) sulphonation of a lysate from recombinant host cells or lysis of recombinant host cells in the presence of guanidinium chloride (preferably 6 M Gu.HCl) and sulphonation of the cell lysate, (b) treatment with a zwitterionic detergent, preferably after removal of the cell debris, (c) purification of the sulphonated recombinant protein, or purification of the sulphonated recombinant protein with subsequent removal of the zwitterionic detergent, with said purification being preferably chromatography, more preferably a Ni-IMAC chromatography with said recombinant protein being a His-tagged recombinant protein, (d) desulphonation of the sulphonated recombinant protein, preferably with a molar excess of 16 a reducing agent such as DTT, (e) storage in the presence of a molar excess of DTT. Empigen is a particularly preferred example of a zwitterionic detergent. Inclusion of such a zwitterionic detergent and DTT was found to improve the purification protocol for HCV NS3 helicase and HCV envelope proteins. The present invention also relates to an HCV polynucleic acid encoding an HCV NS3 polyprotein as shown in Figure 1 (SEQ ID NOs 3-18) or a unique part of an HCV polynucleic acid having a sequence as represented in Figures 2-1, 3-1 , 4-1 , 5-1, 6-1 , 7-1, and 8-1 (SEQ ID NOs 19, 21, 23, 25, 27, 29 and 31). The present invention also relates to an HCV polynucleic acid as defined above characterized in Figures 2-1, 3-1, 4-1, 5-1, 6-1, 7-1, and 8-1 and by the fact that its product does not react with false positive HCV samples, or a part thereof which encodes NS3 epitopes which do not react with false positive HCV samples. It was particularly surprising that the proteins coded by the clones represented by SEQ ID NOs 19, 21, 23, 25, 27, 29 and 31 have the property of not reacting with false positive HCV samples, yet they were able to react with most of the known NS3 antibody-positive samples after DTT treatement. The present invention further relates to a recombinant vector comprising a polynucleic acid as described. The present invention further relates to a host cell comprising a vector of the invention. The present invention furhter relates to a method for detecting a nucleic acid of the invention. This detection method can be any method known in the art such as described in detail in WO 96/13590 to Maertens & Stuyver. More particularly, the present invention relates to a method for detecting a nucleic acid of the invention comprising: - contacting said nucleic acid with a probe; - determining the complex formed between said nucleic acid and said probe. In accordance, the present invention relates to an isolated nucleic acid as described above or a fragment thereof for use as a probe or a primer. The present invention further relates to a diagnostic kit for the detection of a nucleic acid sequence as described above, comprising at least one primer and/or at least one probe according to the invention. For a detailed description to an overview of these applications reference is made to WO 96/13590. 17 In addition to the reactivity gained by reduction, the NS3 reactivity is also severely determined by the sequence of the NS3 antigen. The present invention therefore also relates to an HCV polypeptide having part or all of the amino acid sequences as shown in Figures 1, 2-2, 3-2, 4-2, 5-2, 6-2, 7-2 and 8-2 (SEQ ID NOs 20, 22, 24, 26, 28, 30, 32).The present invention also relates to an HCV NS3 helicase protein as depicted in Figure 1 (SEQ ID NOs 1-18) or an unique part thereof. The present invention also relates to an HCV NS3 helicase protein or part thereof containing either S1200, A1218, A1384, P1407, V1412, P1424, or F1444, or a combination of these amino acids with any of the following amino acids L1201, S1222, 11274, S1289, T1321, A1323, T1369, L1382, V1408, A1409, or F1410. Said numbering is according to the commonly accepted HCV amino acid numbering system. The present invention further relates to a pharmaceutical composition comprising a polypeptide of the invention or any functionally equivalent variant or fragment thereof. The terms "a pharmaceutical composition" relates to a composition or medicament (both terms can be used interchangeably) comprising a polypeptide of the present invention and a pharmaceutically acceptable carrier or excipient (both terms can be used interchangeably). This pharmaceutical composition can be used as a medicament. This pharmaceutical composition can be used as a medicament for the treatment or prevention of HCV infection. Suitable carriers or excipients known to the skilled man are saline, Ringer's solution, dextrose solution, Hank's solution, fixed oils, ethyl oleate, 5% dextrose in saline, substances that enhance isotonicity and chemical stability, buffers and preservatives. Other suitable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids and amino acid copolymers. The "pharmaceutical composition" or "medicament" may be administered by any suitable method within the knowledge of the skilled man. The preferred route of administration is parenterally or a vaccine. In parental or vaccine administration, the medicament of this invention will be formulated in a unit dosage injectable form such as a solution, suspension or emulsion, in association with the pharmaceutically acceptable excipients as defined above. For vaccine applications or for the generation of polyclonal antiserum/antibodies, for example, the effective amount may vary depending on the species, age, and general condition of the individual, the severity of the condition being treated, the particular polypeptide selected and its mode of administration, etc. It is also believed that effective amounts will be found within 18 a relatively large, non-critical range. An appropriate effective amount can ~ be readily determined using only routine experimentation. Preferred ranges of NS3 and/or El and/ or E2 and/or E1/E2 single or specific oligomeric envelope proteins for prophylaxis of HCV disease are 0.01 to 1000 μg/dose, preferably 0.1 to 100 μg/dose, more preferably 1 to 50 μg/dose. Several doses may be needed per individual in order to achieve a sufficient immune response and subsequent protection against HCV disease. In the case of a therapeutic vaccine, the number of required doses may amount to more than 10. Continuous infusion may also be used. If so, the medicament may be infused at a dose between 5 and 20 μg/kg/minute, more preferably between 7 and 15 μg/kg/minute. It should also be clear that the pharmaceutical composition of the present invention may comprise a functionally equivalent variant or fragment of the sequences given by SEQ LD NOs 3-18, 20, 22, 24, 26, 28, 30, 32. The latter terms refer to a molecule which contains the full protein sequence of the polypeptide of the invention or part of the protein sequence of the polypeptide of the invention, to which certain modifications have been applied, and which retains all or part of the biological properties of the polypeptide of the invention. Such modifications include but are not limited to the addition of polysaccharide chains, the addition of certain chemical groups, the addition of lipid moieties, the fusion with other peptide or protein sequences and the formation of intramolecular cross-links. The present invention also relates to an immunoassay comprising an HCV polypeptide as defined above. Said immunoassay can be of any type of format known in the art (see for instance WO 96/13590 and Coligan et al. 1992). In particlular, the present invention relates to a method for detecting a polypeptide of the invention comprising: - contacting said polypeptide with a ligand binding to said polypeptide; - determining the complex formed between said polypeptide and said ligand. In accordance the present invention also relates to a ligand binding to a polypeptide according of the invention. The term "a ligand" refers to any molecule able to bind the polypeptides of the present invention. The latter term specifically refers to polyclonal and/or monoclonal antibodies specifically raised (by any method known in the art) against the polypeptides of the present invention and also encompasses any antibody-like, and other, constructs as described in detail in EP 97870092.0 to Lorre et al. Such antibodies may be very useful for the detection of antigen in biological fluids. Detection of antigen can be done by any immunoassay known in the art such as assays which utilize biotin and avidin or streptavidin, ELISA' s and immunoprecipitation, immunohistchemical techiques and agglutination assays. 19 A detailed description of these assays is given in WO 96/13590 which is hereby incorporated by reference. Furthermore, said antibodies may be very useful for therapy of HCV or other diseases and may therefore be humanized if generated in a non-human host. In accordance, the present invention relates to compositions of these antibodies in a pharmaceutical acceptable excipient, for use as a medicament. The present invention also relates to any method for producing and using said polyproteins of the invention. Methods for producing and using HCV polyproteins are disclosed in WO 96/13590. Said uses include not only diagnostic uses but also therapeutic and prophylactic uses. The NS3 proteins of the invention are also particularly suited to be incoporated in vaccine compositions. Said vaccine composition may contain, besides the active ingredient, any type of adjuvant known in the art. The contents of WO 96/13590 are hereby incoφorated by reference in the present description. The NS3 proteins of the present invention may also be used in any application where it is applicable to use an NS3 helicase, such as for drug screening puφoses. 20 FIGURE LEGENDS Figure 1. Amino acid sequence of HCV NS3 clones isolated from HCV subtype la and lb infected sera. Figure 2-1. DNA coding sequence of the mTNFH6NS3 clone 19b fusion protein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. Figure 2-2. Amino Acid sequence of the mTNFH6NS3 clone 19b fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence contains the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. Figure 3-1. DNA coding sequence of the mTNFH6NS3 clone B9 fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. Figure 3-2. Amino Acid sequence of the mTNFH6NS3 clone B9 fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. Figure 4-1. DNA coding sequence of the mTNFH6NS3 Type 3a clone 21 fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. Figure 4-2. Amino Acid sequence of the mTNFH6NS3 Type 3a clone 21 fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. Figure 5-1. DNA coding sequence of the mTNFH6NS3 Type 3a clone 32 fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. 21 Figure 5-2. Amino Acid sequence of the mTNFH6NS3 Type 3a clone 32 fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. Figure 6-1. DNA coding sequence of the mTNFH6NS3 Type 2a fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. Figure 6-2. Amino Acid sequence of the mTNFH6NS3 Type 2a fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. Figure 7-1. DNA coding sequence of the mTNFH6NS3 Type 2b fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. Figure 7-2. Amino Acid sequence of the mTNFH6NS3 Type 2b fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. Figure 8-1. DNA coding sequence of the mTNFH6NS3 Type 2c fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. Figure 8-2. Amino Acid sequence of the mTNFH6NS3 Type 2c fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker. 22 EXAMPLES Example 1. Expression of HCV NS3 Type lb clone 19b in E. coli 1.1 Cloning of the HCV NS3 Type lb clones 19a and 19b genes The NS3 helicase domain (amino acids 1188-1465) was amplified by RT-PCR from HCV subtype lb serum IG8309 (Innogenetics, Ghent, Belgium) using synthetic oligonucleotide primers HCPr59 (5'-GGGCCCCACCATGGGGGTTGCGAAGGCGGTGGACTT-3') (SEQ LD NO 1) and HCPr60 (5'-CTATTAGCTGAAAGTCGACTGTCTGGGTGACAGCA-3') (SEQ LD NO 2). This yielded a PCR fragment 19 which was cloned into E. coli. The sense primer HCPr59 introduces an Apal restriction site which includes an artifical methionine. Antisense oligonucleotide HCPrόO introduces a stopcodon after aa 1465. The PCR fragment was subsequently cut with Apal and the resulting 833 bp Apal fragment was cloned in the Apal-cut expressionvector pmTNFHRP (Innogenetics, Ghent, Belgium). Four hepatitis C clones (HCC1) were sequenced: HCC119a and HCC119b (see deduced amino acid sequence given in Figure 1 and Figure 2-2). Clone HCC119b (ρmTNFHRPHCC119b) was retained for further subcloning. 1.2 Construction of the expression plasmid pEmTNFMPHHCC119b Starting from vector pmTNFHRPHCC119b the NS3 clone 19b coding sequence was isolated as a 900 bp Ncol fragment and inserted into the Ncol-cut expressionvector pEmΗ FMPH (Innogenetics, Ghent, Belgium) resulting in vector pEmTNFMPHHCC119b. This plasmid expresses HCVNS3 clone 19b as an N-terminal fusionprotein with the N-terminal 25 aa of murine TNF followed by a hexahistidine purification tag and a formic acid cleavage site (SEQ ID NOs 19 and 20; Figure 2). 1.3 Expression of HCV NS3 clone 19b in Kcoli E.coli strain MCI 06 l(pAcI) cells (Wertman et al., 1986) were transformed with plasmid pEmTNFMPHHCC119b. MC1061(pAcI) cells harboring pEmTNFMPHHCC119b were grown overnight in Luria Broth (LB) supplemented with 10 μg/ml tetracycline at 28°C. Cultures were 23 diluted 20 times in fresh LB, then grown at 28°C to an OD 600 of 0.2, after which the temperature was raised to 42°C. At 2 to 3 hours post-induction, the cells were harvested. Expression of the HCV NS3 clone 19b fusion protein was analysed by western blotting using specific monoclonal antibodies and HCV positive human sera. Example 2. Expression of HCV NS3 clone B9 in E.coli 2.1 Cloning of the HCV NS3 Type la clone B9 gene TheNS3 helicase domain (amino acids 1188-1465) was amplified by RT-PCR from HCV subtype la serum IG21054 (Innogenetics, Ghent, Belgium) using synthetic oligonucleotide primers HCPr59 (5'-GGGCCCCACCATGGGGGTTGCGAAGGCGGTGGACTT-3') (SEQ LD NO 1) and HCPrόO (5'-CTATTAGCTGAAAGTCGACTGTCTGGGTGACAGCA-3') (SEQ ID NO 2). This yielded a PCR fragment B which was cloned into E. coli. The sense primer HCPr59 introduces an Apal restriction site which includes an artifical methionine. Antisense oligonucleotide HCPrόO introduces a stopcodon after aa 1465. The PCR fragment was subsequently cloned in the pGEM-T vector (Promega, Madison, WI, US). Four clones were sequenced: B7, B9, B12, and B14 (see deduced amino acid sequences in Figure 1 and Figure 3-2). Clone B9 (pGEMTNS3B9) was retained for further subcloning. 2.2 Construction of the expressionplasmid pIGFHlllNS3B9 Starting from vector pGEMTNS3B9, the clone B9 coding sequence was isolated as a 850 bp Ncol/Spel blunted fragment and inserted into the Ncol/Stul cut expression vector pIGFHl 11 (Innogenetics, Ghent, Belgium) resulting in vector pIGFHl 11NS3B9 This plasmid expresses HCV NS3 clone B9 as an N-terminal fusion protein with the N-terminal 25 aa of murine TNF followed by a hexahistidine purification tag and a formic acid cleavage site (SEQ ID NOs. 21 and 22; Figure 3). 24 2.3 Expression of HCV NS3 clone B9 in E.coli E.coli strain MCI 06 l(pAcI) (Wertman et al., 1986) cells were transformed with plasmid pIGFHl 11NS3B9. MC1061(pAcI) cells harboring pIGFHl 11NS3B9 were grown overnight in Luria Broth (LB) supplemented with 10 μg/ml tetracycline at 28°C. Cultures were diluted 20 times in fresh LB, then grown at 28°C to an OD 600 of 0.2, after which the temperature was raised to 42°C. At 2 to 3 hours post-induction, the cells were harvested. Expression of the HCV NS3 clone B9 fusion protein was analysed on Western blot using specific monoclonal antibodies and HCV positive human sera. Example 3. Expression of HCV NS3 Type la clones A26, C16, and D18 in E.coli Clones A26, C16, and D18 were isolated from HCV subtype la infected sera IG21051, IG17790, and IG21068, respectively, in a similar way as described for clone B9 using primers HCPr59 and HCPrόO. Initially, clones, A5, A26, Cl, C3, C4, C12, C16, D17, D18, and D19, were cloned and sequenced (see deduced amino acid sequences given in Figure 1). Clones A26, C16, and D18 were retained for further subcloning. Example 4. Expression of HCV NS3 Type 3a clones 21 and 32 in E.coli 4.1 Cloning of the HCV NS3 Type 3a clones 21 and 32 genes The NS3 helicase domain (amino acids 1188-1465) was amplified by RT-PCR from HCV subtype 3a sera IG21349 and IG20014 (Innogenetics, Ghent, Belgium) using synthetic oligonucleotide primers 403 (5'GGGCCCCACCATAGGTGTAGCAAAAGCCCTACAGTT-3') (SEQ LD NO 33) and 404 (5'-CTATTAGCTGAAGTCAACGTACTGTTCAACAGC-3') (SEQ LD NO 34). This yielded in both cases a PCR fragment of approx. 850 bp which was subsequently subcloned in the pGEM-T vector (Promega, Madison, WL US). From each cloned PCR fragment several clones were sequenced but from each serum only one cloned fragment proved to be completely correct upon sequencing. This was clone 21 (pGEM-TNS3T3a.21) for serum 25 IG21349 and clone 32 (pGEM-TNS3T3a.32) for serum IG20014 (Figures 4 and 5). 4.2 Construction of the expressionplasmids pIGFHl HNS3T3a.21 and pIGFHl HNS3T3a.32 Starting from vectors pGEM-TNS3T3a.21 and pGEM-TNS3T3a.32, the clone 21 and 32 coding sequences were isolated as 850 bp NcoI/SalL fragments and inserted into the Ncol/Sall cut expression vector pIGFHl 11 (Innogenetics, Ghent, Belgium) resulting in vectors pIGFHl HNS3T3a.21 and pIGFHl HNS3T3a.32, respectively. These plasmids express HCV NS3 Type 3a clones 21 and 32 as N-terminal fusion proteins with the N-terminal 25 aa of murine TNF followed by a hexahistidine purification tag and a formic acid cleavage site (SEQ LD NOs 23-26; Figures 4 and 5). 4.3 Expression of HCV NS-3 Type 3a clones 21 and 32 in E.coli E.coli strain MClOόlψAcI) (Wertman et al., 1986) cells were transformed with plasmids pIGFHl HNS3T3a.21 and pIGFHl HNS3T3a,32, respectively. MClOόl(pAcI) cells harboring pIGFHl HNS3T3a.21 or pIGFHl HNS3T3a.32 were grown overnight in Luria Broth (LB) supplemented with 10 μg/ml tetracycline at 28°C. Cultures were diluted 20 times in fresh LB, then grown at 28°C to an OD600 of 0.2, after which the temperature was raised to 42°C. At 2 to 3 hours post-induction, the cells were harvested. Expression of the HCV NS3 Type 3 a clones 21 and 32 fusionproteins was analysed on Western blot using specific monoclonal antibodies and HCV positive human sera. Example 5. Expression of HCV NS3 Type 2a clone 3 in E.coli 5.1 Cloning of the HCV NS3 Type 2a clone 3 gene The NS3 helicase domain (amino acids 1188-1465) was amplified by RT-PCR from a HCV subtype 2a serum IG21342 (Innogenetics, Ghent, Belgium) using synthetic oligonucleotide primers 412 (5'-GGGCCCCACCATGGGCGTGGCCAAGTCCATAGACTT-3') (SEQ ID NO 26 35) and 413 (5'-CTATTAGCTGAAGTCTACAACTTGAGTGACCGC-3') (SEQ ID NO 36). This yields a PCR fragment of approx. 850 bp which was subsequently subcloned in the pGEM-T vector (Promega, Madison, WI, US). Several clones were sequenced and clone 3 (pGEM- TNS3T2a) was retained for further subcloning (Figure 6). 5.2 Construction of expressionplasmid pIGFHl HNS3T2a Starting from vector pGEM-TNS3T2a, the clone 3 coding sequence was isolated as a 850 bp Ncol fragment and inserted into the Ncol cut expression vector pIGFHl 11 (Innogenetics, Ghent, Belgium) resulting in vector pIGFHl 1 lNS3T2a. This plasmid expresses HCV NS3 Type 2a clone 3 as an N-teπriinal fusion protein with the N-terminal 25 aa of murine TNF followed by a hexahistidine purification tag and a formic acid cleavage site (SEQ ID NOs 27 and 28; Figure 6). 5.3 Expression of HCV NS-3 Type 2a clone 3 in E.coli E.coli strain MCI 06 l(pAcI) (Wertman et al., 1986) cells were transformed with plasmid pIGFHl 1 lNS3T2a. MClOόl(pAcI) cells harbouring pIGFHl 1 lNS3T2a were grown overnight in Luria Broth (LB) supplemented with 10 μg/ml tetracycline at 28°C. Cultures were diluted 20 times in fresh LB, then grown at 28°C to an OD600 of 0.2, after which the temperature was raised to 42°C. At 2 to 3 hours post-induction, the cells were harvested. Expression of the HCV NS3 Type 2a clone 3 fusionprotein was analysed on Western blot using specific monoclonal antibodies and HCV positive human sera. Example 6. Expression of HCV NS3 Type 2b clone 9 in E.coli 6.1 Cloning of the HCV NS3 Type 2b clone 9 gene The NS3 helicase domain (amino acids 1188-1465) was amplified by RT-PCR from a HCV subtype 2b serum IG20192 (Innogenetics, Ghent, Belgium) using synthetic oligonucleotide primers 401 (5'-GGGCCCCACCATGGGCGTAGCCAAATCCATTGACTT-3') (SEQ ID NO 27 37) and 402 (5'-CTATTAGCTGAAGTCTACAATTTGAGAGACCGC-3') (SEQ LD NO 38). This yields a PCR fragment of approx. 850 bp which was subsequently subcloned in the pGEM-T vector (Promega, Madison, WI, US). Several clones were sequenced and clone 9 was retained for further subcloning (Figure 7). 6.2 Construction of expressionplasmid pIGFHl HNS3T2b Starting from vector pGEM-TNS3T2b, the clone 9 coding sequence was isolated as a 850 bp Ncol fragment and inserted into the Ncol cut expression vector pIGFHl 11 (Innogenetics, Ghent, Belgium) resulting in vector pIGFHl 1 lNS3T2b. This plasmid expresses HCV NS3 Type 2b clone 9 as an N-teπriinal fusion protein with the N-terminal 25 aa of murine TNF followed by a hexahistidine purification tag and a formic acid cleavage site (SEQ ID NOs 29-30; Figure 7). 6.3 Expression of HCV NS-3 Type 2b clone 9 in E. coli E.coli strain MClOόl(pAcI) cells (Wertman et al., 1986) were transformed with plasmid pIGFHl 1 lNS3T2b. MClOόl(pAcI) cells harbouring pIGFHl 1 lNS3T2b were grown overnight in Luria Broth (LB) supplemented with 10 μg/ml tetracycline at 28°C. Cultures were diluted 20 times in fresh LB, then grown at 28°C to an OD600 of 0.2, after which the temperature was raised to 42°C. At 2 to 3 hours post-induction, the cells were harvested. Expression of the HCV NS3 Type 2b clone 9 fusionprotein was analysed on Western blot using specific monoclonal antibodies and HCV positive human sera. Example 7. Expression of HCV NS3 Type 2c clone 14 in E.coli 7.1 Cloning of the HCV NS3 Type 2c clone 14 gene The NS3 helicase domain (amino acids 1188-1465) was amplified by RT-PCR from a HCV subtype 2c serum IG20031 (Innogenetics, Ghent, Belgium) using synthetic oligonucleotide primers 401 (5'-GGGCCCCACCATGGGCGTAGCCAAATCCATTGACTT-3') (SEQ ID NO 37) and 402 (5'-CTATTAGCTGAAGTCTACAATTTGAGAGACCGC-3') (SEQ ID NO 38). 28 This yields a PCR fragment of approx. 850 bp which was subsequently subcloned in the pGEM-T vector (Promega, Madison, WI, US). Several clones were sequenced and clone 14 (pGEM- TNS3T2c) was retained for further subcloning (Figure 8). 7.2 Construction of expressionplasmid pIGFHl HNS3T2c Starting from vector pGEM-TNS3T2c, the clone 14 coding sequence was isolated as a 850 bp Ncol fragment and inserted into the Ncol cut expression vector pIGFHl 11 (Innogenetics, Ghent, Belgium) resulting in vector pIGFHl 1 lNS3T2c. This plasmid expresses HCV NS3 Type 2c clone 14 as an N-terminal fusion protein with the N-terminal 25 aa of murine TNF followed by a hexahistidine purification tag and a formic acid cleavage site (SEQ ID NOs 31 and 32; Figure 8). 7.3 Expression of HCV NS-3 Type 2c clone 14 in E.coli E.coli strain MCI 06 l(pAcI) cells (Wertman et al., 1986) were transformed with plasmid pIGFHl 11NS3T2C. MC1061(pAcI) cells harbouring pIGFHl 1 lNS3T2c were grown overnight in Luria Broth (LB) supplemented with 10 μg/ml tetracycline at 28°C. Cultures were diluted 20 times in fresh LB, then grown at 28°C to an OD600 of 0.2, after which the temperature was raised to 42°C. At 2 to 3 hours post-induction, the cells were harvested. Expression of the HCV NS3 Type 2c clone 14 fusionprotein was analysed on Western blot using specific monoclonal antibodies and HCV positive human sera. Example 8. Purification of the NS3 helicase protein domain Nine volumes of 8M Guanidinium hydrochloride (Gu.HCl) and 1 volume of 0.2 M NaHPO 4 were added to each gram equivalent of wet E. coli cell paste and the solution was homogenized by continuously vortexing. Solid Na^Og and Na 2 SO 3 were added to the solution up to a final concentration of 65 and 360 mM, respectively. CuSO 4 (stock solution: 0.1 M in 25% NH 3 ) was added up to a final concentration of lOOμM. The solution was stirred overnight in the dark at room temperature and after incubation at -70°C cleared by centrifugation at 4°C (30 min, 29 20.000 rpm, JA20 rotor). Empigen BB™ (Albright & Wilson Ltd., Okibury, UK) and imidazole were added to the supernatant up to a final concentration of 1% (w/v) and 20 mM, respectively. The pH was adjusted to 7.2 with IN HCl. A sample corresponding to 3 L cell culture equivalent was loaded at 2 mL/min on a 25 mL Ni-LDA Sepharose FF (XK 16/20 column, Pharmacia, Upsala, Sweden), which had been equilibrated with buffer A containing 20 mM imidazole (buffer A: 50 mM phosphate, 6M Gu.HCl, 1% Empigen, pH 7.2). The Ni- DA Sepharose column was washed consecutively with: - buffer A containing 20mM imidazole - buffer A containing 35 mM imidazole - buffer A containing 50 mM imidazole - buffer B containing 50 mM imidazole (buffer B: 50 mM phosphate, 6M Gu.HCl, pH 7.2) - buffer B containing 200 mM imidazole. Each washing step was maintained during the chromatography untill the absorbance at 280 nm reached baseline level. The column was regenerated with 50 mM EDTA, 500 mM NaCl, pH 7.0. Fractions were analysed by SDS-PAGE using non-reducing conditions and silver staining. The mTNF-NS3 B9 fusion protein was recovered in the 200 mM imidazole elution. Western blotting using rabbit anti-human TNF (lμg NS3/lane) and rabbit anti-E. coli (10 μg NS3/lane) showed that the NS3 exhibited a purity of over 99 % after this single chromatography step. The 200 mM imidazole elution fractions were pooled and desalted. A 40 mL Ni-LDA eluate sample was loaded at 10 mL /min on a 300 mL Sephadex G25 column (XK 50, Pharmacia, Upsala, Sweden) which had been equilibrated with 50 mM phosphate, 6M ureum, lmM EDTA, pH 7.2. 10 mL-fractions were collected and the protein concentration was determined by the micro BCA method (Pierce, Rockford, LL, US). The protein concentration was adjusted to 500 μg/mL with the desalting buffer before desulphonation and reduction. The overall yield was 50-55 mg purified NS3 fusion protein/L culture equivalent. Finally, DTT (stock solution: 100 mM in destilled water) was added in a 100-fold molar excess versus the cysteine content in the NS3 antigen (e.g. NS3 19b contains 7 cysteins). The solution was flushed with nitrogen and incubated for lh at 28°C. The NS3 sample was subsequently diluted in the appropiate buffer for ELISA and LIA coating. 30 Example 9. NS3 helicase antibody reactivity tested in LIA In order to test the NS3 helicase antibody reactivity, a line of 50 μg/ml NS3 antigen solution in phosphate buffered saline was applied onto nylon membrane strips. The strips were dried for at least 1 hour at a temperature between 18-24°C and were subsequently blocked with PBS/caseine in the presence (10 mM) or absence of the reducing agent DTT. The strips were subsequently washed with PBS containing Tween 20 and either no DTT or 10 mM DTT and with water containing either no DTT or 10 mM DTT and 1 mM EDTA. The membranes were dried for 30 minutes and cut into strips for testing of different patient samples. The results of an experiment wherein strips were incubated with the anti-HCV seroconversion panel PHV903 (Boston Biomedica Inc., Boston, US) are given in Table 1. Example 10. NS3 helicase antibody reactivity tested in ELISA In order to test the NS3 helicase antibody reactivity, ELISA plates were coated with the NS3 antigens purified as in Example 4 in the following way. Microtiter plate wells were coated withNS3 protein at a concentration of 0.3 μg/ml NS3 protein in coating buffer containing 50 mM carbonate buffer, either 200 mM DTT or no DTT, and 1 mM EDTA. The microtiter plates are incubated for 18 hours at 20° C, and blocked with 300 μl of PBS/caseine buffer per well. The plates were incubated for 2 hours at 20°C and subsequently fixed with 300 μl of fixation buffer containing either 200 mM DTT or no DTT, and 1 mM EDTA for 2 hours at 20°C. The results are shown in Tables 2 and 3. Table 2 gives the Signal to Noise values of assays including NS3 coated and fixed with or without DTT, with the BBI seroconversion panels PHV901 to PHV912. Table 3 shows a summary of the number of days in which HCV antibodies can be detected earlier by the assay incorporating DTT. Clearly, a total number of 34 days of earlier detection in 12 HCV seroconversions can be obtained by incorporating DTT in the assay. 31 Table 1. BBI panels tested in LIA coated with HCV NS3 as described in example 9. PHV +DTT 1 -DTT 1 903-01 - - 903-02 - - 903-03 +/- - 903-04 2 - 903-05 2 +/- 903-06 2 +/- 903-07 4 2 903-08 4 2 1 -: no reaction; +positive reaction; intensity ratings are given in comparison with different cut off lines sprayed onto the same strip. 32 Table 2: BBI panelsrtested in ELISA coated with HCV NS3 as described in example 10. MEMBER ID# BLEED DATE + DTT fOD M ) - DTT (OD«„ PHV901-01 09/23/93 0.1 0.3 PHV901-02 11/27/93 0.1 0.3 PHV901-03 12/29/93 2.0 2.9 PHV901-04 12/31/93 2.1 3.0 PHV901-05 01/05/94 2.2 3.1 PHV901-06 01/07/94 2.4 3.2 PHV901-07 02/01/94 4.1 6.0 PHV901-08 02/09/94 3.9 5.9 PHV901-09 03/01/94 4.0 7.9 PHV901-10 03/08/94 4.1 7.8 PHV901-11 04/14/94 4.2 8.3 PHV903-01 02/07/92 0.2 0.2 PHV903-02 02/12/92 0.9 0.9 PHV903-03 02/14/92 1.3 1.6 PHV903-04 02/19/92 2.5 2.7 PHV903-05 02/21/92 2.8 2.8 PHV903-06 02/26/92 3.2 4.6 PHV903-07 02/28/92 3.5 5.4 PHV903-08 03/04/92 3.5 4.1 PHV904-01 04/18/95 0.1 0.2 PHV904-02 04/20/95 0.1 0.3 PHV904-03 04/25/95 0.1 0.2 PHV904-04 04/27/95 0.1 0.2 PHV904-05 05/02/95 0.4 0.4 PHV904-06 05/09/95 0.8 0.5 PHV904-07 05/11/95 0.8 0.5 PHV905-01 11/17/95 0.1 0.2 PHV905-02 11/21/95 0.1 0.3 PHV905-03 11/24/95 0.1 0.3 PHV905-04 11/28/95 0.2 0.3 PHV905-05 12/01/95 0.5 0.3 PHV905-06 12/05/95 1.0 0.4 PHV905-07 12/08/95 2.5 0.8 PHV905-08 12/12/95 3.5 2.2 PHV905-09 12/15/95 3.5 3.2 33 MEMBER H # BLEED DATE 1 + DTT - DTT PHV 907-01 04/06/96 0.1 0.2 PHV907-02 04/10/96 0.1 0.2 PHV907-03 04/13/96 0.1 0.2 PHV907-04 04/19/96 3.0 2.2 PHV907-05 04/24/96 3.7 4.1 PHV907-06 04/27/96 3.6 4.1 PHV907-07 09/17/96 3.9 7.6 PHV908-01 01/26/96 0.1 0.1 PHV908-02 01/29/96 0.1 0.1 PHV908-03 01/31/96 0.1 0.1 PHV908-04 02/06/96 0.1 0.1 PHV908-05 02/08/96 0.1 0.1 PHV908-06 02/14/96 0.2 0.1 PHV908-07 02/20/96 1.4 0.2 PHV908-08 02/22/96 1.6 0.2 PHV908-09 02/27/96 1.9 0.2 PHV908-10 03/01/96 2.3 0.2 PHV908-11 03/07/96 2.3 0.4 PHV908-12 03/11/96 2.8 0.5 PHV908-13 03/14/96 2.8 0.5 PHV909-01 01/28/96 0.1 0.4 PHV909-02 02/15/96 2.3 5.4 PHV909-03 02/17/96 2.4 5.3 PHV910-01 08/26/96 0.1 0.2 PHV910-02 08/30/96 0.4 0.2 PHV910-03 09/03/96 2.7 3.1 PHV910-04 09/06/96 3.6 6.4 PHV910-05 09/10/96 3.9 8.1 PHV911-01 10/30/96 0.1 0.2 PHV911-02 11/02/96 0.1 0.2 PHV911-03 11/13/96 2.1 4.0 PHV911-04 11/20/96 3.6 7.8 PHV911-05 11/23/96 3.7 7.7 PHV912-01 01/06/96 0.2 0.3 PHV912-02 01/10/96 0.2 0.2 PHV912-03 01/13/96 4.5 9.9 34 MEMBER π)# BLEED OATE +DTT -DTT PHV902-01 02/10/92 0.1 0.2 PHV902-02 02/12/92 0.1 0.2 PHV902-03 02/17/92 0.1 0.3 PHV902-04 02/19/92 0.3 0.6 PHV902-05 02/24/92 2.6 3.9 PHV902-06 02/26/92 3.1 5.9 PHV902-07 03/02/92 3.4 6.5 PHV906-01 10/07/95 0.5 0.3 PHV906-02 10/09/95 0.5 0.4 PHV906-03 10/14/95 1.6 0.6 PHV906-04 10/17/95 1.5 1.2 PHV906-05 10/21/95 2.2 3.0 PHV906-06 10/24/95 2.5 4.5 PHV906-07 10/28/95 2.9 5.7 35 Table 3. Overview of the BBI panels - numbers of days with earlier detection PHV +DTT -DTT 901 0 0 902 0 0 903 0 0 904 0 0 905 7 0 906 3 0 907 0 0 908 24 0 910 0 0 911 0 0 912 0 0 36 REFERENCES Burns, J. , Butler, J. , Moran, J. , and Whitesides, G. (1991) Selective reduction of disulfides by tris(2-carboxyethyl)phosphine. J. Org. Chem. 56, 2648-2650 Chan, W. (1968) A method for the complete S sulfonation of cysteine residues in proteins Biochemistry 7, 4247-4254 Claeys, H , Volkaerts, A , Verhaert, H , De Beenhouwer, H , and Vermylen, C (1992) Evaluation of anti-HCV capsid indeterminate samples The Lancet 340, 249 Cole, R. (1967) Sulfitolysis. Meth. Enzymol. 11, 206. Coligan, J , Kruisbeek, A , Margulis, D , Shevach, E and Strober, W (1992) Current protocols in immunology. Wiley Interscience De Beenhouwer, H , Verhaert, H , Claeys, H , and Vermylen, C (1992) Confirmation of hepatitis C virus positive blood donors by immunoblotting and polymerase chain reaction Vox Sang 63, 198-203 Di Bisceglie, AM, Carithers, RL Jr, Gores, GJ (1998) Hepatocellular carcinoma Hepatology 28, 1161-1165 Gailit, J. (1993) Restoring free sulfhydryl groups in synthetic peptides Anal. Biochem. , 214, 334-335. Holmgren, A. (1979) Thioredoxin catalyzes the reduction of insulin disulfides by 37 dithiothreitol and dihydrolipoamide J Biol Chem 254, 9627-9632 Inglis, A. , and Liu, T. (1970) The stability of cysteine and cystine during acid hydrolysis of proteins and peptides J Biol Chem 245, 112-116 McFarlane, I , Smith, H , Johnson, P , Bray, G , Vergani, D , and Williams, R (1990) Hepatitis C virus antibodies in chronic active hepatitis pathogenic factor or false-positive result? The Lancet 335, 754-757 Maertens, G and Stuyver, L (1997) Genotypes and Genetic variation of hepatitis C virus In Molecular Medicine of Hepatitis (Eds Zuckerman, A and Harrison, T ), Molecular Medical Science Series (Eds James, K and Morris A) John Wiley and Sons Ltd , Chichester, England, Chapter 13, pp 183-233 Marin, M , Bresciani, S , Puoti, M , Rodella, A , Gussago, A , Ravaggi, A , Pizzocolo, G , Albertini, A , and Cariani, E (1994) Clinical significance of serum HCV RNA as marker of HCV infection J Clin Microbiol 32, 3008-3012 Peeters, D , Dekeyser, F , DeLeys, R , Maertens, G , and Pollet, D (1993) Confirmation of anti-hepatitis C virus antibodies using the LNNO-LIA HCV Ab III including Core, E2/NS1, NS3, NS4, and NS5 epitopes International Symposium on Viral Hepatitis and Liver Disease, Tokyo, abstract 413 Pollet, D , Saman, E , Peeters, D , Warmenbol, H , Heyndricks, L , Wouters, C , Beelaert, G , van der Groen, G , and Van Heuverswyn, H (1990) Confirmation and differentiation of antibodies to human immunodeficiency virus 1 and 2 with a strip-based assay including recombinant antigens and synthetic peptides Clin Chem 37, 1700-1707 38 Saito, I , Miyamura, T , Ohbayashi, A , Harada, H , Katayama, T , Kikuchi, S , Watanabe, Y , Koi, S , Onji, M , Ohta, Y , Choo, Q -L , Houghton, M , and Kuo, G (1990) Proc Natl Acad Sci USA 87, 6547-6549 Singh, R. , and Kats, L. (1995) Catalysis of reduction of disulfide by selenol Anal. Biochem. , 232, 86-91. Stuyver, L , Fretz, C , Esquivel, C , Boudifa, A , Jaulmes, D , Azar, N , Lunel, F , Leroux- Roels, G , Maertens, G , and Fournel, J (1996) HCV genotype analysis in apparently healthy anti-HCV positive Parisian blood donors Transfusion 36, 552-558 Thakur, M. , DeFulvio, J., Richard, M., and Park, C. (1991) Technetium-99m labeled monoclonal antibodies: evaluation of reducing agents. Nucl. Med. Biol. , 18, 227- 233. Waumans, L , Claeys, H , Verhaert, H , Mertens, W , and Vermylen, C (1993) Hepatitis C virus confirmation in blood donor screening Vox Sang 64, 145-149 Wertman K F , Wyman A R and Botstein D (1986) Host/vector interactions which affect the viability of recombinant phage lambda clones Gene 49 253-262 Zaaijer, H , Vrielink, H , van Exel-Oehlers, P , Cuypers, H , and Lelie, P (1994) Confirmation of hepatitis C infection a comparison of five immunoblot assays Transfusion 34, 603-607

Claims: 39 CLAIMS 1 . Solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent. 2 . Method for producing or carrying out an immunoassay according to claim 1, wherein said reducing agent is added to said solid phase during the steps of coating, blocking and/or fixation of said antigen to said solid phase or during pretreatment of the solid phase. 3. Method according to claim 2 wherein said reducing agent is added to said solid phase during the step of coating the antigen to the solid phase. 4. Method according to claim 2, wherein said reducing agent is added to said solid phase during the step of blocking said solid phase comprising the antigen applied thereto in the presence or absence of a reducing agent. 5. Method according to claim 2, wherein said reducing agent is added to said solid phase during the step of fixation of said solid phase comprising the antigen applied thereto in the presence or absence of a reducing agent. 6. Method according to claim 2, wherein said reducing agent is added during pretreatment of the solid phase comprising the antigen applied thereto in the presence or absence of a reducing agent. 7. Method according to any of claims 1 to 6 wherein said reducing agent is DTT, DTE or TCEP. 40 8. Method according to any of claims 1 to 7 wherein said reducing agent is used in a concentration range of 0.1 mM to 1 M, more particularly from 0.5 mM to500 mM, even more particular from 1 mM to 250 mM, some applications may require ranges from 0.5 to 50 mM, 1 to 30 mM, 2 to 20 mM, or 5 to 15 mM, or about 10 mM. 9. Method according to any of claims 2 to 8 wherein said antigen is an HCV NS3 protein. 10. Solid phase immunoassay produced by a method according to any of claims 2 to 9. 11. ELISA produced by a method according to any of claims 2 to 9. 12. ELISA according to claim 11 wherein said reducing agent is added in the coating and/or fixation steps. 13. QUICK test produced by a method according to any of claims 2 to 9. 14. QUICK test according to claim 13 wherein said reducing agent is added in the blocking step. 15. Line Immunoassay produced by a method according to any of claims 2 to 9. 16. Line Immunoassay according to claim 15 wherein said reducing agent is added in the blocking step. 17. Use of an assay according to claims 10 to 16 for in vitro diagnosis of antibodies raised against an antigen as described in claim 1. 41 18 . HCV NS3 protein treated by a method comprising the steps of sulphonation and subsequent desulphonation. 19 . HCV NS3 protein according to claim 18 which is additionally treated with a zwitter-ionic detergent, preferably Empigen. 20. Method for purifying a cysteine containing recombinantly expressed protein comprising at least 2, preferably 3 or 4 and even more preferably all of the following steps: (a) sulphonation of a lysate from recombinant host cells or lysis of recombinant host cells in the presence of guanidinium chloride followed by a subsequent sulphonation of the cell lysate, (b) treatment with a zwitterionic detergent, preferably after removal of the cell debris, (c) purification of the sulphonated version of the recombinant protein or purification of the sulphonated version of the recombinant protein with subsequent removal of the zwitterionic detergent, with said purification being preferably chromatography, more preferably a Ni- LMAC chromatography with said recombinant protein being a His-tagged recombinant protein, (d) desulphonation of the sulphonated version of the recombinant protein, preferably with a molar excess of DTT, (e) storage in the presence of a molar excess of DTT, or immediate use in an assay. 21. An HCV polynucleic acid encoding a polypeptide as depicted in Figure 1 (SEQ ID NOs 3- 18) or a unique part of an HCV polynucleic acid, more particularly a polynucleic acid having a sequence as represented in Figures 2-1, 3-1, 4-1, 5-1, 6-1, 7-1 or 8-1 (SEQ ID NOs 19, 21, 23, 25, 27, 29 and 31). 22. An HCV polynucleic acid according to claim 21 as depicted in Figures 2-1, 3-1, 4-1, 5-1, 6-1, 7-1 or 8-1 and characterized by the fact that its product does not react with falsly positive 42 HCV samples, or a part thereof which encodes a NS3 epitope which does not react with falsly positive HCV samples. 23. A recombinant vector comprising a polynucleic acid according to claim 21 or 22. 24. A host cell comprising a vector according to claim 23. 25. A method for detecting a nucleic acid sequence according to claim 21 or 22 comprising: -contacting said nucleic acid with a probe -determining the complex formed between said nucleic acid and said probe. 26. An isolated nucleic acid according to claim 21 or 22 or a fragment thereof for use as a probe or a primer for the detection of a nucleic acid according to claim 21 or 22. 27. A diagnostic kit for the detection of a nucleic acid sequence according to claim 21 or 22, comprising at least one primer and/or at least one probe according to claim 26. 28. An HCV polypeptide having part or all of the amino acid sequences of a polypeptide encoded by a polynucleic acid according to claim 21 or 22. 29. An HCV NS3 helicase protein or part thereof containing either S1200, A1218, A1384, PI 407, VI 412, PI 424, or F1444, or a combination of these amino acids with any of the following amino acids L1201, S1222, 11274, S1289, T1321, A1323, T1369, L1382, V1408, A1409, F1410. 50. A pharmaceutical composition comprising a polypeptide according to claim 28 or 29, or 43 any functionally equivalent variant or fragment thereof. 31. A pharmaceutical composition comprising a polypeptide according to claim 28 or 29, or any functionally equivalent variant or fragment thereof for use as a medicament to prevent or treat HCV infection. 32. A method for detecting a polypeptide according to claim 28 or 29 comprising: -contacting said polypeptide with a ligand binding to said polypeptide -determining the complex formed between said polypeptide and said ligand. 33. A ligand binding to a polypeptide according to claim 28 or 29. 34. A composition comprising at least a ligand according to claim 33, in a pharmaceutical acceptable excipient, for use as a medicament. 35. A method for the production of a polypeptide according to claim 28 or 29 for diagnostic or therapeutic puφoses.

Inventors: BOSMAN ALFONS, LOUWAGIE JOOST, MAERTENS GEERT, SABLON ERWIN, ZREIN MAAN, BOSMAN, ALFONS, LOUWAGIE, JOOST, MAERTENS, GEERT, SABLON, ERWIN, ZREIN, MAAN
Applicants: BOSMAN ALFONS, INNOGENETICS NV, LOUWAGIE JOOST, MAERTENS GEERT, SABLON ERWIN, ZREIN MAAN, BOSMAN, ALFONS, INNOGENETICS N.V., LOUWAGIE, JOOST, MAERTENS, GEERT, SABLON, ERWIN, ZREIN, MAAN
Application year: 1999
Main classification: G01N33
IPC codes: A61K38, A61K39, A61K45, A61P31, A61P43, C07K1, C07K14, C12N1, C12N5, C12N9, C12N15, C12P21, C12Q1, G01N33